N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Magnetic Stimulation to Treat VT Storm
Ventricular Tachycardia
Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants
Phase 4 N=53 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia
Ventricular Tachycardia
Primary: Percentage of Participants Free From VT at 1 Year Post-Treatment — 62 percentage of participants free from VT
Phase 3 N=110 SVT-15652 Otic Solution for the Treatment of Otomycosis.
Otomycosis
Primary: Therapeutic Cure (Clinical and Mycological Cure) — 59; 8 Participants
N/A N=74 Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia
Supraventricular Tachycardia
Primary: Total Fluoroscopy Time — 18.3; 7.5 minutes
Phase 3 N=118 SVT-15652 Otic Solution for the Treatment of Otomycosis
Otomycosis
Primary: Therapeutical Cure (Clinical and Mycological Cure) — 48; 10 Participants
N/A N=22 Dexmedetomidine and Adenosine: Therapeutic Use for SVT
Supraventricular Tachycardia
Primary: Termination of SVT — 16; 21 participants
N/A N=1 Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
N/A N=76 CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery
Femoral Artery Stenosis · Popliteal Artery Stenosis · Femoral Artery Occlusion
Primary: Number and Percentage of Participants With Freedom of Major Adverse Event (MAE) Rate — 72 Participants
Phase 3 N=472 Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Superficial Vein Thrombosis
Primary: Rate of Objectively Confirmed VTE Complications — 7; 4 Participants — p=0.0252
Phase 3 N=30 A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)
Supra-ventricular Tachycardia
Primary: The Number of Patients With First Dose Successful Termination of the Supraventricular Tachycardia to a Sinus Rhythm of Less Than 140 With the AHA Versus a Simplified…
N/A N=18 Multimodality Assessment of Ventricular Scar Arrhythmogenicity.
Ventricular Tachycardia
Primary: Electrogram Duration at Digital Twin Predicted Sites Compared to Non-predicted Sites — 77.5; 65.7 ms
Phase 4 N=246 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Ventricular Tachycardia · Premature Ventricular Contraction · Stroke
Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001
N/A N=481 A Clinical Evaluation of ST Changes in a Group of Patients Having Ventricular Arrhythmias
Coronary Artery Disease
Primary: Among Patients With an Appropriate ICD Therapy (Shock or ATP) for Ventricular Tachycardia or Fibrillation, the Number of Patients Who Have Characterized ST Segment…
Phase 3 N=72 Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia
Supraventricular Tachycardia
Primary: Incidence of Recurrent Supraventricular Tachycardia (SVT) Requiring Medical Intervention to Terminate the Episode. — 12; 18 percentage of participants
N/A N=381 Safety and Effectiveness of STSF Catheter Evaluated for Treating Symptomatic Persistent Atrial Fibrillation (PsAF)
Atrial Fibrillation
Primary: Primary Safety Endpoint - Percentage of Participants With Any PAE Within 7 Days — 4.7 Percentage of participants
N/A N=134 Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)
Bradycardia
Primary: Percentage of Intrinsic Ventricular Events — 82.7; 22.8 % of intrinsic ventricular events — p=<0.0001
N/A N=10 Ablation at Virtual-hEart pRedicted Targets for VT
Ventricular Tachycardia · Ischemic Cardiomyopathy
Primary: Number of Participants With Ventricular Tachycardia Inducibility — 6 Participants
N/A N=20 Imaging With a Radio Tracer to Guide VT Ablations
Ventricular Tachycardia · Arrhythmia
Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants
Phase 2 N=199 Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
Paroxysmal Supraventricular Tachycardia (PSVT)
Primary: The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration — 20; 15; 20; 13 Participants — p=<0.05
Phase 4 N=1,902 Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III
Heart Disease
Primary: For the Primary Endpoint the Reduction of Ventricular Therapies (ATP and Shocks) Delivered for Treating Fast Spontaneous Arrhythmia Episodes Was Measured. — 67.1; 41.9…
N/A N=51 CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
In-stent Restenosis
Primary: The Primary Safety Endpoint for the CVT-ISR Study: Freedom From Target Lesion Failure (TLF) Rate — 4; 1; 0; 3 Participants
N/A N=300 RAVE: Radial Artery Vascular Complication and Resource Utilization
Angiogram · Percutaneous Coronary Intervention
Primary: Time to Hemostasis — 19; 120; 44; 45 minutes
N/A N=10 Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
N/A N=145 Bipolar Ventricular Tachycardia (VT) Study
Ventricular Tachycardia
Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants
N/A N=3,000 PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement
Stroke
Primary: The Rate of Stroke Through 72 Hours Post TAVR Procedure or Discharge (Whichever Comes First) — 34; 43 Participants
N/A N=180 Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial
Ventricular Tachycardia (VT)
Primary: Freedom From Recurrent VT, Cardiovascular Rehospitalization, and All-cause Mortality — 33; 25; 28; 27 Participants
N/A N=17 REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation
Ventricular Tachycardia
Primary: Freedom From First Event Requiring ICD Therapy — 62.5; 50; 62.5; 37.5 probability of freedom
N/A N=31 Left Ventricular Synchronous Versus Sequential MultiSpot Pacing for Cardiac Resynchronization Therapy (CRT)
Heart Failure
Primary: Percentage Change in Positive Left Ventricular dP/dt Max (mmHG/Sec) — 10.59; 12.20; 11.51; 15.64 % change LV dP/dt max
Phase 2 N=69 ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Atrial Fibrillation
Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001